[144] Labcorp Holdings Inc. SEC Filing
Labcorp Holdings Inc. insider notice reports a proposed sale of 5,643 common shares for an aggregate market value of $1,505,439.54, to be executed through Fidelity Brokerage Services on the NYSE with an approximate sale date of 08/11/2025. The shares were acquired on 03/30/2023 by restricted stock vesting as compensation. The filing also shows the seller previously sold 6,105 shares on 05/12/2025 for gross proceeds of $1,518,496.65. The issuer's total outstanding common shares are reported as 83,100,000. By signing, the seller represents no undisclosed material adverse information and notes the compliance statements relevant to Rule 144 and Rule 10b5-1.
Labcorp Holdings Inc. comunica, tramite un avviso interno, la proposta di vendita di 5,643 azioni ordinarie per un valore di mercato complessivo di $1,505,439.54, da eseguirsi tramite Fidelity Brokerage Services sulla NYSE con data di vendita approssimativa 08/11/2025. Le azioni sono state acquisite il 03/30/2023 mediante vesting di azioni ristrette come compenso. La pratica segnala inoltre che il venditore aveva precedentemente venduto 6,105 azioni il 05/12/2025 per proventi lordi di $1,518,496.65. Il numero totale di azioni ordinarie in circolazione dell'emittente è riportato pari a 83,100,000. Con la firma, il venditore dichiara l'assenza di informazioni materiali avverse non divulgate e indica le dichiarazioni di conformità relative alla Rule 144 e alla Rule 10b5-1.
Labcorp Holdings Inc. informa en un aviso de insider sobre la propuesta de venta de 5,643 acciones ordinarias por un valor de mercado agregado de $1,505,439.54, que se ejecutaría a través de Fidelity Brokerage Services en la NYSE con fecha aproximada de venta 08/11/2025. Las acciones fueron adquiridas el 03/30/2023 mediante vesting de acciones restringidas como compensación. La presentación también muestra que el vendedor vendió previamente 6,105 acciones el 05/12/2025 por ingresos brutos de $1,518,496.65. Las acciones ordinarias totales en circulación del emisor se reportan en 83,100,000. Al firmar, el vendedor declara que no existe información material adversa no divulgada y señala las declaraciones de cumplimiento relevantes a la Rule 144 y la Rule 10b5-1.
Labcorp Holdings Inc. 내부자 공시에 따르면, 총 시가 약 $1,505,439.54 상당의 보통주 5,643주를 NYSE의 Fidelity Brokerage Services를 통해 08/11/2025로 예정된 대략적인 매도일에 매각할 예정이라고 보고했습니다. 해당 주식은 03/30/2023에 보수로서 제한주식 베스팅(restricted stock vesting)을 통해 취득되었습니다. 제출서류에는 또한 판매자가 이전에 05/12/2025에 6,105주를 매각하여 총수익 $1,518,496.65을 얻었다고 기재되어 있습니다. 발행회사의 총 발행 보통주 수는 83,100,000으로 보고됩니다. 서명함으로써 판매자는 공개되지 않은 중대한 불리한 정보가 없음을 진술하고 Rule 144 및 Rule 10b5-1 관련 준수 진술을 명시합니다.
Labcorp Holdings Inc. signale, dans un avis d'initié, une vente proposée de 5,643 actions ordinaires pour une valeur marchande totale de $1,505,439.54, devant être exécutée via Fidelity Brokerage Services à la NYSE avec une date de vente approximative le 08/11/2025. Les actions ont été acquises le 03/30/2023 par vesting d'actions restreintes en tant que rémunération. Le dossier indique également que le vendeur avait précédemment cédé 6,105 actions le 05/12/2025 pour un produit brut de $1,518,496.65. Le nombre total d'actions ordinaires en circulation de l'émetteur est indiqué à 83,100,000. En signant, le vendeur déclare l'absence d'informations défavorables significatives non divulguées et mentionne les déclarations de conformité pertinentes à la Rule 144 et à la Rule 10b5-1.
Labcorp Holdings Inc. meldet in einer Insider-Mitteilung den geplanten Verkauf von 5,643 Stammaktien mit einem Gesamtmarktwert von $1,505,439.54, der über Fidelity Brokerage Services an der NYSE mit einem ungefähren Verkaufsdatum 08/11/2025 ausgeführt werden soll. Die Aktien wurden am 03/30/2023 durch Restricted-Stock-Vesting als Vergütung erworben. Die Einreichung zeigt außerdem, dass der Verkäufer zuvor am 05/12/2025 6,105 Aktien für Bruttoerlöse von $1,518,496.65 verkauft hatte. Die insgesamt ausstehenden Stammaktien des Emittenten werden mit 83,100,000 angegeben. Mit seiner Unterschrift erklärt der Verkäufer, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen, und verweist auf die Compliance-Angaben zu Rule 144 und Rule 10b5-1.
- None.
- None.
Insights
TL;DR: Routine insider notice to sell a small number of vested shares; unlikely to be material to valuation.
The filing shows an officer or insider proposing to sell 5,643 shares valued at $1.51M, with an earlier sale of 6,105 shares in the prior three months. Against 83.1M shares outstanding, these transactions represent a de minimis ownership change. The shares were received via restricted stock vesting, indicating compensation-related disposition rather than capital raising. From a market-impact perspective, the size and frequency suggest routine liquidity management rather than a material signal about firm fundamentals.
TL;DR: Filing appears compliant with Rule 144 disclosure; no governance red flags evident from this notice alone.
The notice provides required broker details (Fidelity Brokerage Services), acquisition history, and a representation that no material nonpublic information is known. The presence of prior recent sales is disclosed, and the acquisition method (restricted stock vesting) is consistent with executive compensation practices. Absent additional context—such as large concentrated disposals, sudden executive departures, or conflicting disclosure—this Form 144 is a standard insider sale notice and does not in itself indicate governance concerns.
Labcorp Holdings Inc. comunica, tramite un avviso interno, la proposta di vendita di 5,643 azioni ordinarie per un valore di mercato complessivo di $1,505,439.54, da eseguirsi tramite Fidelity Brokerage Services sulla NYSE con data di vendita approssimativa 08/11/2025. Le azioni sono state acquisite il 03/30/2023 mediante vesting di azioni ristrette come compenso. La pratica segnala inoltre che il venditore aveva precedentemente venduto 6,105 azioni il 05/12/2025 per proventi lordi di $1,518,496.65. Il numero totale di azioni ordinarie in circolazione dell'emittente è riportato pari a 83,100,000. Con la firma, il venditore dichiara l'assenza di informazioni materiali avverse non divulgate e indica le dichiarazioni di conformità relative alla Rule 144 e alla Rule 10b5-1.
Labcorp Holdings Inc. informa en un aviso de insider sobre la propuesta de venta de 5,643 acciones ordinarias por un valor de mercado agregado de $1,505,439.54, que se ejecutaría a través de Fidelity Brokerage Services en la NYSE con fecha aproximada de venta 08/11/2025. Las acciones fueron adquiridas el 03/30/2023 mediante vesting de acciones restringidas como compensación. La presentación también muestra que el vendedor vendió previamente 6,105 acciones el 05/12/2025 por ingresos brutos de $1,518,496.65. Las acciones ordinarias totales en circulación del emisor se reportan en 83,100,000. Al firmar, el vendedor declara que no existe información material adversa no divulgada y señala las declaraciones de cumplimiento relevantes a la Rule 144 y la Rule 10b5-1.
Labcorp Holdings Inc. 내부자 공시에 따르면, 총 시가 약 $1,505,439.54 상당의 보통주 5,643주를 NYSE의 Fidelity Brokerage Services를 통해 08/11/2025로 예정된 대략적인 매도일에 매각할 예정이라고 보고했습니다. 해당 주식은 03/30/2023에 보수로서 제한주식 베스팅(restricted stock vesting)을 통해 취득되었습니다. 제출서류에는 또한 판매자가 이전에 05/12/2025에 6,105주를 매각하여 총수익 $1,518,496.65을 얻었다고 기재되어 있습니다. 발행회사의 총 발행 보통주 수는 83,100,000으로 보고됩니다. 서명함으로써 판매자는 공개되지 않은 중대한 불리한 정보가 없음을 진술하고 Rule 144 및 Rule 10b5-1 관련 준수 진술을 명시합니다.
Labcorp Holdings Inc. signale, dans un avis d'initié, une vente proposée de 5,643 actions ordinaires pour une valeur marchande totale de $1,505,439.54, devant être exécutée via Fidelity Brokerage Services à la NYSE avec une date de vente approximative le 08/11/2025. Les actions ont été acquises le 03/30/2023 par vesting d'actions restreintes en tant que rémunération. Le dossier indique également que le vendeur avait précédemment cédé 6,105 actions le 05/12/2025 pour un produit brut de $1,518,496.65. Le nombre total d'actions ordinaires en circulation de l'émetteur est indiqué à 83,100,000. En signant, le vendeur déclare l'absence d'informations défavorables significatives non divulguées et mentionne les déclarations de conformité pertinentes à la Rule 144 et à la Rule 10b5-1.
Labcorp Holdings Inc. meldet in einer Insider-Mitteilung den geplanten Verkauf von 5,643 Stammaktien mit einem Gesamtmarktwert von $1,505,439.54, der über Fidelity Brokerage Services an der NYSE mit einem ungefähren Verkaufsdatum 08/11/2025 ausgeführt werden soll. Die Aktien wurden am 03/30/2023 durch Restricted-Stock-Vesting als Vergütung erworben. Die Einreichung zeigt außerdem, dass der Verkäufer zuvor am 05/12/2025 6,105 Aktien für Bruttoerlöse von $1,518,496.65 verkauft hatte. Die insgesamt ausstehenden Stammaktien des Emittenten werden mit 83,100,000 angegeben. Mit seiner Unterschrift erklärt der Verkäufer, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen, und verweist auf die Compliance-Angaben zu Rule 144 und Rule 10b5-1.
FAQ
Who is the filer selling Labcorp (LH) shares in this Form 144?
How many Labcorp (LH) shares are proposed for sale and what is their aggregate value?
When were the shares being sold originally acquired by the filer?
Did the filer sell any Labcorp (LH) shares in the past three months?
Through which broker and exchange will the proposed sale occur?
How large is the proposed sale relative to outstanding shares?
